Search research articles
Contact Us
Filters
Showing results (191-200 of 231) with videos related to
Page
of 24
Sort By:
Breast Cancer Research and Treatment
|
February 16, 2021
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
Andrew Wardley, Javier Cortes, Louise Provencher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2021
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy
Tomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, et al.
Health Policy OPEN
|
March 11, 2024
The evolving value assessment of cancer therapies: Results from a modified Delphi study
Myrto Lee, Hugo Larose, Martin Gräbeldinger, et al.
The New England Journal of Medicine
|
September 16, 2024
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Peter Schmid, Javier Cortes, Rebecca Dent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, et al.
JCO Precision Oncology
|
April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis
Sherene Loi, Roberto Salgado, Peter Schmid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2019
Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Rina Hui, Alex Pearson, Javier Cortes, et al.
Oncotarget
|
July 28, 2016
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
Marta Hergueta-Redondo, David Sarrio, Ángela Molina-Crespo, et al.
The New England Journal of Medicine
|
May 31, 2023
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer
Nicholas C Turner, Mafalda Oliveira, Sacha J Howell, et al.
Cancer Treatment Reviews
|
June 19, 2023
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis
Carlotta Becherini, Luca Visani, Saverio Caini, et al.
Page
of 24
Search research articles
Search
Showing results (191-200 of 231) with videos related to
Sort By:
Page
of 24
Breast Cancer Research and Treatment
|
February 16, 2021
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
Andrew Wardley, Javier Cortes, Louise Provencher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2021
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy
Tomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, et al.
Health Policy OPEN
|
March 11, 2024
The evolving value assessment of cancer therapies: Results from a modified Delphi study
Myrto Lee, Hugo Larose, Martin Gräbeldinger, et al.
The New England Journal of Medicine
|
September 16, 2024
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Peter Schmid, Javier Cortes, Rebecca Dent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, et al.
JCO Precision Oncology
|
April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis
Sherene Loi, Roberto Salgado, Peter Schmid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2019
Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Rina Hui, Alex Pearson, Javier Cortes, et al.
Oncotarget
|
July 28, 2016
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
Marta Hergueta-Redondo, David Sarrio, Ángela Molina-Crespo, et al.
The New England Journal of Medicine
|
May 31, 2023
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer
Nicholas C Turner, Mafalda Oliveira, Sacha J Howell, et al.
Cancer Treatment Reviews
|
June 19, 2023
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis
Carlotta Becherini, Luca Visani, Saverio Caini, et al.
Page
of 24